Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Chelerythrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 5/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | BCHE | P06276 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | RAC1 | P63000 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | BAD | Q92934 | 2/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.98 |
| ▸ | MEN1 | O00255 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chelerythrine SCHEMBL30207103 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL29357531 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL30527168 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL30527167 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL288915 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL4016265 | 0.98 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL4980861 | 0.98 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL288916 | 0.98 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL3319851 | 0.98 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL513051 | 0.95 | ALDH1A1 (0.90) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 792 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12472259-B2 | PKC inhibitors for the treatment of septic cholestasis with polymethine dye targeting | SMARTDYELIVERY GMBH (DE) | 2025-11-18 | — | — | US | claimed |
| US-20250268913-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH CTM TARGETING | SMARTDYELIVERY GMBH (DE) | 2025-08-28 | — | — | US | claimed |
| US-20240082310-A1 | BONE MARROW DERIVED NEUROKININ-1 RECEPTOR POSITIVE (NK1R+) MESENCHYMAL STEM CELLS FOR THERAPEUTIC APPLICATIONS | BIOCARDIA INC (US) | 2024-03-14 | — | — | US | claimed |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | claimed |
| CN-114786654-A | Compositions and methods for systemic delivery of Bcl-2 and Bcl-xL antagonists | 密执安大学评议会 | 2022-07-22 | — | — | CN | claimed |
| EP-3878947-A2 | MATURATION OF MAMMALIAN HEPATOCYTES | Takara Bio Europe AB (SE) | 2021-09-15 | — | — | EP | claimed |
| US-20210189332-A1 | MATURATION OF MAMMALIAN HEPATOCYTES | TAKARA BIO EUROPE AB (SE) | 2021-06-24 | — | — | US | claimed |
| WO-2021119439-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF BCL-2 AND BCL-XL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-17 | — | — | WO | claimed |
| US-10913932-B2 | Maturation of mammalian hepatocytes | TAKARA BIO EUROPE AB (SE) | 2021-02-09 | — | — | US | claimed |
| US-6407058-B1 | Modifying the permeability of physiological barriers | EISAI CO., LIMITED (JP) | 2002-06-18 | — | — | US | claimed |
| JP-2001501618-A | — | — | 2001-02-06 | — | — | JP | claimed |
| WO-1999041984-A9 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | HUTCHINSON FRED CANCER RES (US) | 1999-11-04 | — | — | WO | claimed |
| EP-0949917-A1 | SUBSTANCES AND THEIR USES | Eisai Co., Ltd. (JP) | 1999-10-20 | — | — | EP | claimed |
| WO-1999041984-A1 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1999-08-26 | — | — | WO | claimed |
| WO-1998014186-A1 | SUBSTANCES AND THEIR USES | EISAI CO., LIMITED (JP) | 1998-04-09 | — | — | WO | claimed |
| WO-1997004761-A9 | METHODS AND COMPOSITIONS FOR TREATING CELL PROLIFERATIVE DISORDERS | — | 1997-05-29 | — | — | WO | claimed |
| WO-1997004761-A1 | METHODS AND COMPOSITIONS FOR TREATING CELL PROLIFERATIVE DISORDERS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1997-02-13 | — | — | WO | claimed |
| US-4683133-A | PUMPING ALKALOID SALT SOLUTIONS ON GUMS | VIPONT LABORATORIES, INC. (US) | 1987-07-28 | — | — | US | claimed |
| US-4590061-A | BENZO-C-PHENANTHRIDINE ALKALOIDS | VIPONT LABORATORIES, INC. (US) | 1986-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | BCL2, BCL2L2, BCL2L1 | ACHE 4546/4885CHRM1 4884/4885ALDH1A1 2779/4885 |
| US-12472259-B2 | PKC inhibitors for the treatment of septic cholestasis with polymethine dye targeting | PRKCH, PRKCZ, PIKFYVE | ACHE 4152/4885CHRM1 2671/4885ALDH1A1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.